Treating the Patient with High-risk MDS: Practical Strategies and Emerging Therapeutic Options

Treating the Patient with High-risk MDS: Practical Strategies and Emerging Therapeutic Option
Treating the Patient with High-risk MDS: Practical Strategies and Emerging Therapeutic Options
CME, CPE
David A. Sallman, MD
Release Date: October 23, 2019
Expiration Date: October 23, 2020

Almost one-third of patients are classified as higher risk with a median overall survival of less than 1.5 years. In this activity, Dr. David Sallman covers which factors will impact the selections of therapy. Additionally, he will review ongoing clinical trials of novel agents and combinations while outlining where these practice strategies and trials can be utilized.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.
Begin, Earn CreditView Only, No CreditGet Certificate
 

MediCom Worldwide, Inc. would like to thank Celgene Corporation and Onconova Therapeutics Inc. for their educational support of ManagingMDS.com

©2020 MediCom Worldwide, Inc. All rights reserved